Tandem Diabetes Care (NASDAQ: TNDM) had some encouraging news to report on the regulatory front Thursday, and after it hit ...

The prognosticator behind that piece of bad news was Citigroup's Joanne Wuensch, who issued one of her bank's 90-day catalyst watches on Tandem stock before the market open. Wuensch wrote in her ...

Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide ...

Analyst Jeff Johnson from Robert W. Baird reiterated a Hold rating on Tandem Diabetes Care (TNDM – Research Report) and increased the price target to $39.00 from $0.00. Jeff Johnson has given ...

The main goal of diabetes treatment is to keep your blood sugar levels in target range. To help monitor them, your doctor will order blood work on a regular basis, including an A1C test.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

SAN DIEGO, September 19, 2024--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin ...

In its press release trumpeting the EU's move, Tandem quoted its chief medical officer Jordan Pinsker as saying, "Ultra-rapid-acting insulin is a popular choice for people living with diabetes due ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...